AnaSpec has announced the release of three antibodies (two monoclonal and one polyclonal) against FXYD2γa.
FXYD2γa is a regulating subunit of the NA+-K+-ATPase and has been identified as a unique and specific pancreatic beta cell surface biomarker.
In individuals with Type 1 diabetes or in pancreatic sections of streptozotocin-treated Macacus cynomolgus monkeys, loss of FXYD2γa has been closely correlated with a loss of insulin positive cells.
Anti-hFXYD2γa antibodies are purified antibodies reacting with an 11 amino acid residue peptide of FXYD2γa.
Monoclonal anti-FXYD2γa antibodies from Clone 4F9G9 show high specificity towards FXYD2γa beta-cell biomarker while monoclonal anti-FXYD2γa antibodies from Clone 3C1D10 show high sensitivity towards FXYD2γa beta-cell biomarker.
A rabbit polyclonal anti-hFXYD2γa antibody is also available (see Table 1). These antibodies can be used for beta cell specific targeting and non-invasive imaging.
The use of targeting strategies against the biomarker (FXYD2γa) allows early identification of beta cell and the follow up of therapies for diabetes patients.